|EGF receptor family|
The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. In humans, the family includes Her1 (EGFR, ErbB1), Her2 (Neu, ErbB2), Her3 (ErbB3), and Her4 (ErbB4). The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are homologous: erythroblastic leukemia viral oncogene. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease, while excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor.
ErbB protein family signaling is important for development. For example, ErbB-2 and ErbB-4 knockout mice die at midgestation leads to deficient cardiac function associated with a lack of myocardial ventricular trabeculation and display abnormal development of the peripheral nervous system. In ErbB-3 receptor mutant mice, they have less severe defects in the heart and thus are able to survive longer throughout embryogenesis. Lack of Schwann cell maturation leads to degeneration of motor and sensory neurons. Excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor. ErbB-1 and ErbB-2 are found in many human cancers, and their excessive signaling may be critical factors in the development and malignancy of these tumors.
The ErbB protein family consists of 4 members
- ErbB-1, also named epidermal growth factor receptor (EGFR)
- ErbB-2, also named HER2 in humans and neu in rodents
- ErbB-3, also named HER3
- ErbB-4, also named HER4
v-ErbBs are homologous to EGFR, but lack sequences within the ligand binding ectodomain.
All four ErbB receptor family members are nearly same in the structure having single-chain of modular glycoproteins. This structure is made up of an extracellular region or ectodomain or ligand binding region that contains approximately 620 amino acids, a single transmembrane-spanning region containing approximately 23 residues, and an intracellular cytoplasmic tyrosine kinase domain containing up to approximately 540 residues. The extracellular region of each family member is made up of 4 subdomains, L1, CR1, L2, and CR2, where "L" signifies a leucine-rich repeat domain and "CR" a cysteine-rich region, and these CR domains contain disulfide modules in their structure as 8 disulfide modules in CR1 domain, whereas 7 modules in CR2 domain. These subdomains are shown in blue (L1), green (CR1), yellow (L2), and red (CR2) in the figure below. These subdomains are also referred to as domains I-IV, respectively. The intracellular/cytoplasmic region of the ErbB receptor consists mainly of three subdomains: A juxtamembrane with approximately 40 residues, a kinase domain containing approximately 260 residues and a C-terminal domain of 220-350 amino acid residues that become activated via phosphorylation of its tyrosine residues that mediates interactions of other ErbB proteins and downstream signaling molecules.
ErbB and Kinase activation
The four members of the ErbB protein family are capable of forming homodimers, heterodimers, and possibly higher-order oligomers upon activation by a subset of potential growth factor ligands. There are 11 growth factors that activate ErbB receptors.
The ability ('+') or inability ('-') of each growth factor to activate each of the ErbB receptors is shown in the table below:
The dimerization occurs after ligand bind to the extracellular domain of the ErbB monomers and monomer-monomer interaction establishes activating the activation loop in a kinase domain, that activates the further process of transphosphorylation of the specific tyrosine kinases in the kinase domain of ErbB's intracellular part. It is a complex process due to the domain specificity and nature of the members of ErbB family. Notably, the ErbB1 and ErbB4 are the two most studied and intact among the family of ErbB proteins, Which forms functional intracellular tyrosine kinases. ErbB2 has no known binding ligand and absent of an active kinase domain in ErbB3 make this duo preferable to form heterodimers & share each other's active domains to activate transphosphorylation of the tyrosine kinases. The specific tyrosine molecules mainly trans or auto-phosphorylated are at the site Y992, Y1045, Y1068, Y1148, Y1173 in the tail region of the ErbB monomer. For the activation of kinase domain in the ErbB dimer, asymmetric kinase domain dimer of the two monomers is required with the intact asymmetric (N-C lobe) interface at the site of adjoining monomers. Activation of the tyrosine kinase domain leads to the activation of the whole range of downstream signaling pathways like PLCγ, ERK 1/2, p38 MAPK, PI3-K/Akt and more with the cell.
When not bound to a ligand, the extracellular regions of ErbB1, ErbB3, and ErbB4 are found in a tethered conformation in which a 10-amino-acid-long dimerization arm is unable to mediate monomer-monomer interactions. In contrast, in ligand-bound ErbB-1 and unliganded ErbB-2, the dimerization arm becomes untethered and exposed at the receptor surface, making monomer-monomer interactions and dimerisation possible. The consequence of ectodomain dimerization is the positioning of two cytoplasmic domains such that transphosphorylation of specific tyrosine, serine, and threonine amino acids can occur within the cytoplasmic domain of each ErbB. At least 10 specific tyrosines, 7 serines, and 2 threonines have been identified within the cytoplasmic domain of ErbB-1, that may become phosphorylated and in some cases de-phosphorylated (e.g., Tyr 992) upon receptor dimerization. Although a number of potential phosphorylation sites exist, upon dimerization only one or much more rarely two of these sites are phosphorylated at any one time.
Role in cancer
Phosphorylated tyrosine residues act as binding sites for intracellular signal activators such as Ras. The Ras-Raf-MAPK pathway is a major signalling route for the ErbB family, as is the PI3-K/AKT pathway, both of which lead to increased cell proliferation and inhibition of apoptosis.
Genetic Ras mutations are infrequent in breast cancer but Ras may be pathologically activated in breast cancer by overexpression of ErbB receptors. Activation of the receptor tyrosine kinases generates a signaling cascade where the Ras GTPase proteins are activated to a GTP-bound state. The RAS pathway can couple with the mitogen-activated protein kinase pathway or a number of other possible effectors.
The PI3K/Akt pathway is dysregulated in many human tumors because of mutations altering proteins in the pathway. In relation to breast tumors, somatic activating mutations in Akt and the p110α subunit of the PI3K have been detected in 3–5% and 20–25% of primary breast tumors, respectively. Many breast tumors also have lower levels of PTEN, which is a lipid phosphatase that dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate, thereby reversing the action of PI3K.
EGFR has been found to be overexpressed in many cancers such as gliomas and non-small-cell lung carcinoma. Drugs such as panitumumab, cetuximab, gefitinib, erlotinib, afatinib, and lapatinib are used to inhibit it. Cetuximab is a chimeric human: murin immunoglobulin G1 mAb that binds EGFR with high affinity and promotes EGFR internalization. It has recently been shown that acquired resistance to cetuximab and gefitinib can be linked to hyperactivity of ErbB-3. This is linked to an acquired overexpression of c-MET, which phosphorylates ErbB-3, which in turn activates the AKT pathway. Panitumumab is a human mAb with high EGFR affinity that blocks ligand-binding to induce EGFR internalization. Panitumumab efficacy has been tested in a variety of advanced cancer patients, including renal carcinomas and metastatic colorectal cancer in clinical trials.
ErbB2 overexpression can occur in breast, ovarian, bladder, non-small-cell lung carcinoma, as well as several other tumor types. Trastuzumab or Herceptin inhibits downstream signal cascades by selectively binding to the extracellular domain of ErbB-2 receptors to inhibit it. This leads to decreased proliferation of tumor cells. Trastuzumab targets tumor cells and causes apoptosis through the immune system by promoting antibody-dependent cellular cytotoxicity. Two thirds of women respond to trastuzumab. Although herceptin works well in most breast cancer cases, it has not been yet elucidated as to why some HER2-positive breast cancers don't respond well. Research suggests that a low FISH test ratio in estrogen receptor positive breast cancers are less likely to respond to this drug.
- Bublil EM, Yarden Y (April 2007). "The EGF receptor family: spearheading a merger of signaling and therapeutics". Current Opinion in Cell Biology. 19 (2): 124–34. doi:10.1016/j.ceb.2007.02.008. PMID 17314037.
- Cho HS, Leahy DJ (August 2002). "Structure of the extracellular region of HER3 reveals an interdomain tether". Science. 297 (5585): 1330–3. Bibcode:2002Sci...297.1330C. doi:10.1126/science.1074611. PMID 12154198. S2CID 23069349.
- Chan R, Hardy W, Laing M, Muller W. (2017). “The Catalytic Activity of the ErbB-2 Receptor Tyrosine Kinase Is Essential for Embryonic Development”. Molecular Cell Biology. 22: 1073-1078 doi: 10.1128/MCB.22.4.10731078.2002
- Burgess, Antony W.; Cho, Hyun-Soo; Eigenbrot, Charles; Ferguson, Kathryn M.; Garrett, Thomas P. J.; Leahy, Daniel J.; Lemmon, Mark A.; Sliwkowski, Mark X.; Ward, Colin W. (2003-09-01). "An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors". Molecular Cell. 12 (3): 541–552. doi:10.1016/s1097-2765(03)00350-2. ISSN 1097-2765. PMID 14527402.
- Schlessinger, Joseph (2002). "Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor". Cell. 110 (6): 669–672. doi:10.1016/s0092-8674(02)00966-2. PMID 12297041. S2CID 8775985.
- Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John (2006-06-16). "An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor". Cell. 125 (6): 1137–1149. doi:10.1016/j.cell.2006.05.013. ISSN 0092-8674. PMID 16777603. S2CID 14256004.
- Garrett TP, McKern NM, et al. (2002). "Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α". Cell. 110 (6): 763–773. doi:10.1016/S0092-8674(02)00940-6. PMID 12297049. S2CID 17533948.
- Ward C.W.; Lawrence M.C.; et al. (2007). "The insulin and EGF receptor structures: new insights into ligand-induced receptor activation". Trends Biochem. Sci. 32 (3): 129–137. doi:10.1016/j.tibs.2007.01.001. PMID 17280834.
- Qiu, C; Tarrant, M; Choi, S; Sathyamurthy, A; Bose, R; Banjade, S; Pal, A; Bommann, W; Lemmon, M; Cole, P; Leahy, D (2008). "Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase". Structure. 16 (3): 460–467. doi:10.1016/j.str.2007.12.016. PMC 2858219. PMID 18334220.
- Cho HS; Leahy DJ (2002). "Structure of the extracellular region of HER3 reveals an interdomain tether". Science. 297 (5585): 1330–1333. Bibcode:2002Sci...297.1330C. doi:10.1126/science.1074611. PMID 12154198. S2CID 23069349.
- Ferguson KM, Berger MB, et al. (2003). "EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization". Mol. Cell. 11 (2): 507–517. doi:10.1016/S1097-2765(03)00047-9. PMID 12620237.
- Franklin MC, Carey KD, et al. (2004). "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex". Cancer Cell. 5 (4): 317–328. doi:10.1016/S1535-6108(04)00083-2. PMID 15093539.
- Bouyain S, Longo PA, et al. (2005). "The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand". Proc. Natl. Acad. Sci. USA. 102 (42): 15024–15029. Bibcode:2005PNAS..10215024B. doi:10.1073/pnas.0507591102. PMC 1257738. PMID 16203964.
- Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. (September 2002). "Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha". Cell. 110 (6): 763–73. doi:10.1016/S0092-8674(02)00940-6. PMID 12297049. S2CID 17533948.
- Linggi B, Carpenter G (December 2006). "ErbB receptors: new insights on mechanisms and biology". Trends in Cell Biology. 16 (12): 649–56. doi:10.1016/j.tcb.2006.10.008. PMID 17085050.
- Akhtar, Saghir; Chandrasekhar, Bindu; Attur, Sreeja; Dhaunsi, Gursev S.; Yousif, Mariam H. M.; Benter, Ibrahim F. (2015-01-01). "Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor". PLOS ONE. 10 (11): e0141657. Bibcode:2015PLoSO..1041657A. doi:10.1371/journal.pone.0141657. ISSN 1932-6203. PMC 4633289. PMID 26536590.
- Ceresa, Brian P.; Vanlandingham, Phillip A. (2008-01-01). "Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation". Clinical Medicine: Oncology. 2: 47–61. doi:10.4137/cmo.s498. PMC 3161635. PMID 21892266.
- Seshacharyulu, Parthasarathy; Ponnusamy, Moorthy P.; Haridas, Dhanya; Jain, Maneesh; Ganti, Apar K.; Batra, Surinder K. (2012-01-01). "Targeting the EGFR signaling pathway in cancer therapy". Expert Opinion on Therapeutic Targets. 16 (1): 15–31. doi:10.1517/14728222.2011.648617. ISSN 1744-7631. PMC 3291787. PMID 22239438.
- Henriksen, Lasse; Grandal, Michael Vibo; Knudsen, Stine Louise Jeppe; van Deurs, Bo; Grøvdal, Lene Melsæther (2013-01-01). "Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands". PLOS ONE. 8 (3): e58148. Bibcode:2013PLoSO...858148H. doi:10.1371/journal.pone.0058148. ISSN 1932-6203. PMC 3589378. PMID 23472148.
- Yarden, Y.; Sliwkowski, M. X. (2001-02-01). "Untangling the ErbB signalling network". Nature Reviews Molecular Cell Biology. 2 (2): 127–137. doi:10.1038/35052073. ISSN 1471-0072. PMID 11252954. S2CID 4235503.
- Linggi, B.; Carpenter, G. (2006). "ErbB receptors: new insights on mechanisms and biology". Trends Cell Biol. 16 (12): 649–656. doi:10.1016/j.tcb.2006.10.008. PMID 17085050.
- Wu SL, Kim J, et al. (2006). "Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA)". Mol. Cell. Proteomics. 5 (9): 1610–1627. doi:10.1074/mcp.M600105-MCP200. PMID 16799092.
- Schulze WX, Deng L, Mann M (2005). "Phosphotyrosine interactome of the ErbB-receptor kinase family". Mol. Syst. Biol. 1 (2005.0008): E1–E13. doi:10.1038/msb4100012. PMC 1681463. PMID 16729043.
- Jorissen RN, Walker F, et al. (2003). "Epidermal growth factor receptor: mechanisms of activation and signalling". Exp. Cell Res. 284 (10): 31–53. doi:10.1016/S0014-4827(02)00098-8. PMID 12648464.
- Herbst, RS (2004). "Review of epidermal growth factor receptor biology". International Journal of Radiation Oncology, Biology, Physics. 59 (2): 21–6. doi:10.1016/j.ijrobp.2003.11.041. PMID 15142631.
- Hollestelle A, Elstrodt F, Nagel J, Kallemeign W, Schutte M. (2007). “Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines”. Molecular Cancer Research, 5: 195-201 doi: 10.1158/1541-7786.MCR-06-0263
- Hynes, N; MacDonald, G (2009). "ErbB receptors and signaling pathways in cancer". Current Opinion in Cell Biology. 21 (2): 177–184. doi:10.1016/j.ceb.2008.12.010. PMID 19208461.
- Appert A, Hubert P, Cremel G, Bennasroune A. (2015). “Role of ErbB Receptors in Cancer Cell Migration and Invasion”. Front Pharmacology, 6: 283 doi: 10.3389/fphar.2015.00283
- "EGFR Inhibitors: Toxicities and Strategies for Effective Management". Retrieved 2017-10-30.
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA (May 2007). "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling". Science. 316 (5827): 1039–43. Bibcode:2007Sci...316.1039E. doi:10.1126/science.1141478. PMID 17463250. S2CID 23254145.
- "Cancer therapies addressing HGF/c-Met". Retrieved 2007-10-02.
- Nishimura R, Okumura Y, Arima N. (2008). “Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival”. Breast Cancer, 15: 57-64 doi: 10.1007/s12282-007-0014-z
- "Why Do Some HER2-Positive Breast Cancers Not Respond to Herceptin?". Retrieved 2017-10-30.